BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at...
BC Innovations | Nov 14, 2019
Targets & Mechanisms

Impaired wound healing: CD47’s latest safety hurdle?

Just as anti-CD47 antibodies are getting past their first safety hurdle of hematological toxicities, a new study has cautioned that the antibodies could have a dangerous effect on wound healing. In a paper published in...
BC Innovations | Jan 3, 2019
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer; breast cancer Cell culture studies identified a defactinib-based FAK degrader compound that could help treat prostate cancer and triple-negative breast cancer (TNBC). The compound consists of an analog of the FAK inhibitor...
BC Innovations | Oct 25, 2018
Distillery Therapeutics

Neurology

INDICATION: Seizures Fruit fly studies suggest inhibiting FAK, integrin β, TLN1, TNS1 or MMP1 could help treat seizures. In a Drosophila model of mechanically induced seizures, an astrocyte-specific RNAi screen identified four genes encoding components...
BC Extra | Aug 8, 2018
Politics & Policy

Rep. Collins indicted with insider trading in biotech shares

A grand jury charged Rep. Christopher Collins (R-N.Y.) Wednesday with insider trading in shares of Australian biotech Innate Immunotherapeutics Ltd. (ASX:IIL) by alerting family members of a clinical trial failure before the results were made...
BC Week In Review | Jun 15, 2018
Clinical News

Verastem's defactinib combo leads to PR in pancreatic cancer

Verastem Inc. (NASDAQ:VSTM) reported data from 15 evaluable patients with refractory solid tumors in the dose-escalation portion of a Phase I trial showing that defactinib (VS-6063) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co....
BC Week In Review | Nov 10, 2017
Company News

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX;...
BC Extra | Nov 3, 2017
Company News

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX;...
BioCentury | Sep 8, 2017
Finance

Verastem’s value play

Verastem Inc. (NASDAQ:VSTM) has parlayed a small gamble on Phase III asset duvelisib into a double-digit stock bump and what could become the company’s first commercial product. Verastem soared $1.08 (28%) to $4.92 on Sept....
BC Week In Review | May 26, 2017
Clinical News

Verastem reports Phase II data for defactinib in MPM

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago next month, Verastem Inc. (NASDAQ:VSTM) reported data from a Phase II trial in 30 patients with malignant pleural mesothelioma (MPM)...
Items per page:
1 - 10 of 80